Contemporary (2019) prevalence of cardiovascular disease in adults with type 2 diabetes in Brazil: the cross-sectional CAPTURE study

被引:2
作者
Vencio, Sergio [1 ,2 ]
Daher Vianna, Andre Gustavo [3 ,4 ]
Camara Ferreira da Silva, Mariana Arruda [5 ]
Precoma, Dalton Bertolim [6 ]
机构
[1] UFG Fed Univ Goias, Goiania, Go, Brazil
[2] Pharmaceut Inst Sci, ICT, Av Rio Verde S-N, BR-74935530 Aparecida De Goiania, Go, Brazil
[3] Curitiba Diabet Ctr, Curitiba, Parana, Brazil
[4] Nossa Senhora Gracas Hosp, Curitiba, Parana, Brazil
[5] Novo Nordisk, Sao Paulo, SP, Brazil
[6] Angelina Caron Hosp, Res Ctr, Campina Grande Do Sul, PR, Brazil
关键词
Atherosclerosis; Brazil; Cardiovascular disease; Cross-sectional study; Prevalence; Type; 2; diabetes; OUTCOMES;
D O I
10.1186/s13098-021-00775-9
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Type 2 diabetes (T2D) is a known risk factor for cardiovascular disease (CVD), and CVD is a major cause of mortality in patients with T2D. The CAPTURE study investigated the contemporary (2019) prevalence of established CVD in adults with T2D around the world. We report the findings from Brazil. Methods The multinational, non-interventional, cross-sectional CAPTURE study was conducted across 13 countries from five continents. The current manuscript explores data for the CAPTURE study sample in Brazil. Standardized demographic and clinical data were collected from adults with T2D aged >= 18 years attending a single routine healthcare visit in primary or specialized care between December 2018 and September 2019. Data were analyzed descriptively. Results Data from 912 adults with T2D were collected in the CAPTURE study in Brazil, with 822 patients from primary care and 90 patients from specialized care. Median (interquartile range [IQR]) patient characteristics were as follows: age 64 years (57; 71), diabetes duration 11 years (6; 19), glycated hemoglobin 7.7% (6.7; 9.1), and body mass index 29.5 kg/m(2) (26.4; 33.5); 59% were female. The CVD prevalence and atherosclerotic CVD prevalence in the Brazil sample were 43.9% (95% confidence interval [CI] 40.9; 46.8) and 37.6% (95% CI 34.7; 40.5), respectively. The majority of patients with CVD had atherosclerotic CVD (85.8%). For the specific CVD subtypes, coronary heart disease prevalence was 27.9% (95% CI 25.2; 30.5), heart failure was 12.4% (95% CI 10.4; 14.4), cerebrovascular disease was 8.7% (95% CI 6.8; 10.5), and carotid artery disease was 3.4% (95% CI 2.3; 4.5). Glucagon-like peptide-1 receptor agonists and/or sodium-glucose co-transporter-2 inhibitors with proven cardiovascular benefit were prescribed to 15.5% of patients with CVD, compared with 18.4% of patients without CVD. Conclusions CAPTURE was the first multinational, standardized study to provide contemporary data on CVD prevalence in adults with T2D in Brazil, and it demonstrated that almost one in two adults with T2D had established CVD. Except for carotid artery disease, the prevalence of all CVD subtypes in adults with T2D in Brazil appeared higher than the global CAPTURE prevalence. Trial registration NCT03786406, NCT03811288
引用
收藏
页数:9
相关论文
共 28 条
  • [1] Cardiovascular Disease and Type 2 Diabetes: Has the Dawn of a New Era Arrived?
    Abdul-Ghani, Muhammad
    DeFronzo, Ralph A.
    Del Prato, Stefano
    Chilton, Robert
    Singh, Rajvir
    Ryder, Robert E. J.
    [J]. DIABETES CARE, 2017, 40 (07) : 813 - 820
  • [3] Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS111, DOI [10.2337/dc20-S010, 10.2337/dc20-s010]
  • [4] Brazilian guidelines on prevention of cardiovascular disease in patients with diabetes: a position statement from the Brazilian Diabetes Society (SBD), the Brazilian Cardiology Society (SBC) and the Brazilian Endocrinology and Metabolism Society (SBEM)
    Bertoluci, Marcello Casaccia
    Moreira, Rodrigo Oliveira
    Faludi, Andre
    Izar, Maria Cristina
    Schaan, Beatriz D.
    Valerio, Cynthia Melissa
    Bertolami, Marcelo Chiara
    Chacra, Ana Paula
    Bolivar Malachias, Marcus Vinicius
    Vencio, Sergio
    Kerr Saraiva, Jose Francisco
    Betti, Roberto
    Turatti, Luiz
    Helfenstein Fonseca, Francisco Antonio
    Bianco, Henrique Tria
    Sulzbach, Marta
    Bertolami, Adriana
    Nunes Salles, Joao Eduardo
    Hohl, Alexandre
    Trujilho, Fabio
    Lima, Eduardo Gomes
    Miname, Marcio Hiroshi
    Zanella, Maria Teresa
    Lamounier, Rodrigo
    Sa, Joao Roberto
    Amodeo, Celso
    Pires, Antonio Carlos
    Santos, Raul D.
    [J]. DIABETOLOGY & METABOLIC SYNDROME, 2017, 9
  • [5] World Medical Association Declaration of Helsinki Ethical Principles for Medical Research Involving Human Subjects
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2013, 310 (20): : 2191 - 2194
  • [6] [Anonymous], INVOKANA CANAGLIFLOZ
  • [7] [Anonymous], 2019, IDF Diabetes Atlas, V9th
  • [8] Arnett DK, 2019, CIRCULATION, V140, pE596, DOI [10.1161/CIR.0000000000000677, 10.1016/j.jacc.2019.03.010, 10.1161/CIR.0000000000000678, 10.1016/j.jacc.2019.03.009]
  • [9] BR) MdS, VIG BRAS 2019 VIG FA
  • [10] Type 2 diabetes in Brazil: epidemiology and management
    de Almeida-Pititto, Bianca
    Dias, Monike Lourenco
    Franco de Moraes, Ana Carolina
    Ferreira, Sandra R. G.
    Franco, Denise Reis
    Eliaschewitz, Freddy Goldberg
    [J]. DIABETES METABOLIC SYNDROME AND OBESITY, 2015, 8 : 17 - 28